Resource impact summary report
Resource impact summary report
This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect local data and assumptions.
Recommendation
Idebenone is recommended, within its marketing authorisation, as an option to treat visual impairment in Leber's hereditary optic neuropathy (LHON) in people 12 years and over.
Idebenone is recommended only if the company provides it according to the commercial agreement.
Eligible population for idebenone
Table 1 shows the population eligible for idebenone and the number of people expected to have idebenone in each of the next 5 years, including forecast population growth.
| Eligible population and uptake | Number of people eligible for idebenone | Uptake for idebenone (%) | Number of people starting treatment each year (if applicable) | Number of people continuing treatment from previous years (if applicable) | Number of people having idebenone each year |
|---|---|---|---|---|---|
|
Current practice without idebenone |
250 |
0% |
0 |
0 |
0 |
|
Year 1 |
250 |
75% |
188 |
0 |
188 |
|
Year 2 |
51 |
90% |
46 |
188 |
233 |
|
Year 3 |
51 |
90% |
46 |
233 |
279 |
|
Year 4 |
101 |
90% |
47 |
92 |
139 |
|
Year 5 |
72 |
90% |
47 |
93 |
140 |
The following assumptions have been used to calculate the eligible population:
-
There are about 1,500 people in England with LHON.
-
Expert clinical opinion is that about 250 people will be eligible for treatment with idebenone (the prevalent population).
-
About 50 people are expected to be diagnosed with LHON each year (the incident population) who are also eligible for treatment with idebenone.
-
In year 1, 75% of the prevalent population are treated. By year 2, the prevalent population has decreased by 50 people, so it is assumed that all the prevalent population has been treated.
The uptake for idebenone is based on a combination of estimates from the company and NHS England's submissions.
Treatment options for the eligible population
The comparator treatment for the eligible population is best supportive care. Idebenone, which is an oral treatment, will be used in addition to standard care.
For more information about the treatments, such as dose and average treatment duration, see the resource impact template.
Financial resource impact (cash items)
The company has a commercial arrangement. This makes idebenone available to the NHS with a discount.
Users can input the confidential price of idebenone and amend other variables in the resource impact template.
The payment mechanism for the idebenone is determined by the responsible commissioner and depends on the idebenone being classified as high cost.
For further analysis or to calculate the financial impact of cash items, see the resource impact template.
Capacity impact
Table 2 shows the impact on capacity activity in each of the next 5 years.
| Capacity impact | Number of additional opthalmology follow-up appointments |
|---|---|
|
Current practice (without idebenone) |
0 |
|
Year 1 |
0 |
|
Year 2 |
375 |
|
Year 3 |
467 |
|
Year 4 |
184 |
|
Year 5 |
186 |
For further analysis or to calculate the financial capacity impact from a commissioner (national) and provider (local) perspective, see the resource impact template.
Key information
| Time from publication to routine commissioning funding |
90 days |
|---|---|
| Programme budgeting category |
PBC 08X |
| Commissioner |
NHS England |
| Providers |
NHS Hospital trusts |
| Pathway position |
First line |
About this resource impact summary report
This resource impact summary report accompanies the NICE idebenone appraisal guidance on idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over and should be read with it.
ISBN: 978-1-4731-7178-7
This page was last updated: